Juno Therapeutics, Inc.
Formerly FC Therapeutics, Inc.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2017 | $31 M | No. 4 | $10 to $50 million | equity | SEC | |
| Jun 2015 | $899 M | Amount not plausible as filed | $250 million to $1 billion | equity, options | SEC | |
| Aug 2014 | $86 M | No. 3 | $50 to $250 million | equity, options | SEC | |
| Apr 2014 | $28 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Dec 2013 | $7 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Juno Therapeutics, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Oct 2017).
SEC Form D (revenue range) · Oct 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2017
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arch Venture Fund VII LP | Venture capital | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| ARCH Venture Partners VII, LLC | Venture capital | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| ARCH Venture Partners VII, L.P. | Venture capital | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| CL Alaska, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Crestline Investors, Inc. | Fund or asset manager | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Crestline Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Crestline SI (GP), L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Howard H. Pien | Person | not stated | not stated | Held Series A-2 preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Marc Tessier-Lavigne | Person | not stated | not stated | Held Series A-2 preferred stock, director (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 34 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Bernard J. Cassidy | Executive officer | Oct 2017 |
| Hans Bishop | Executive officer | Oct 2017 |
| Robert Azelby | Executive officer | Oct 2017 |
| Steven Harr | Executive officer | Oct 2017 |
| Sunil Agarwal | Executive officer | Oct 2017 |
| Hyam Levitsky | Executive officer | Jul 2016 |
| Mark Frohlich | Executive officer | Jul 2015 |
| Bernard Cassidy | Executive officer | Aug 2014 |
| Anthony J. Evnin | Director | Oct 2017 |
| Hal J. Barron | Director | Oct 2017 |
| Hans Bishop | Director | Oct 2017 |
| Howard J. Pien | Director | Oct 2017 |
| Jay J. Flatley | Director | Oct 2017 |
| Mary Agnes Wilderotter | Director | Oct 2017 |
| Richard J. Klausner | Director | Oct 2017 |
| Robert J. Nelsen | Director | Oct 2017 |
| Rupert Agnes Vessey | Director | Oct 2017 |
| Thomas Agnes Daniel | Director | Oct 2017 |
| Marc J. Tessier-Lavigne | Director | Jul 2016 |
| Anthony Evnin | Director | Aug 2014 |
| Howard Pien | Director | Aug 2014 |
| Marc Tessier-Lavigne | Director | Aug 2014 |
| Richard Klausner | Director | Aug 2014 |
| Robert Nelsen | Director | Aug 2014 |
| Rick Klausner | Director | May 2014 |
| Larry Corey | Director | Dec 2013 |
| Hans Bishop | Promoter | Oct 2017 |
| Richard J. Klausner | Promoter | Oct 2017 |
| Robert J. Nelsen | Promoter | Oct 2017 |
| Mark Frohlich | Promoter | Jul 2015 |
| Richard Klausner | Promoter | Aug 2014 |
| Robert Nelsen | Promoter | Aug 2014 |
| Rick Klausner | Promoter | May 2014 |